BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/4/2023 5:53:01 AM | Browse: 862 | Download: 1718
Publication Name World Journal of Gastroenterology
Manuscript ID 80301
Country United States
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Review
Article Title Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy
Manuscript Source Invited Manuscript
All Author List Seohyuk Lee and Saad Saffo
ORCID
Author(s) ORCID Number
Seohyuk Lee http://orcid.org/0000-0003-3023-1304
Saad Saffo http://orcid.org/0000-0001-5375-3100
Funding Agency and Grant Number
Corresponding Author Saad Saffo, MD, Academic Fellow, Department of Medicine, Section of Digestive Diseases, Yale School of Medicine, 333 Cedar Street, 1080 LMP, New Haven, CT 06520-8019, United States. saad.saffo@yale.edu
Key Words Cirrhosis; Hepatic decompensation; Beta-blockers; Statins; Sodium-glucose cotransporter-2 inhibitors; Rifaximin
Core Tip Hepatic decompensation is the most important clinical predictor of morbidity and mortality among patients with cirrhosis. New pharmacotherapies aimed at preventing hepatic decompensation in high-risk patients are emerging, augmenting traditional management strategies. These treatments represent safe, accessible, and effective options that may improve quality of life and prolong transplant-free survival, regardless of the etiologic factors involved.
Publish Date 2023-01-04 05:53
Citation Lee S, Saffo S. Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy. World J Gastroenterol 2023; 29(1): 61-74
URL https://www.wjgnet.com/1007-9327/full/v29/i1/61.htm
DOI https://dx.doi.org/10.3748/wjg.v29.i1.61
Full Article (PDF) WJG-29-61.pdf
Full Article (Word) WJG-29-61.docx